Get the Stockscreener App
0.4531
9.79%
-0.0469
Bioatla Inc stock is traded at $0.4531, with a volume of 733.55K.
It is down -9.79% in the last 24 hours and down -25.26% over the past month.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
See More
Previous Close:
$0.50
Open:
$0.4855
24h Volume:
733.55K
Relative Volume:
0.68
Market Cap:
$29.01M
Revenue:
-
Net Income/Loss:
$-123.46M
P/E Ratio:
-0.1749
EPS:
-2.59
Net Cash Flow:
$-104.11M
1W Performance:
-4.03%
1M Performance:
-25.26%
6M Performance:
-67.55%
1Y Performance:
-83.89%
1-Day Range:
$0.4425
$0.50
1-Week Range:
$0.425
$0.5136
52-Week Range:
$0.425
$4.02
Bioatla Inc Stock (BCAB) Company Profile
Name
Bioatla Inc
Sector
Industry
Phone
858-558-0708
Address
11085 TORREYANA ROAD, SAN DIEGO
Compare BCAB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BCAB
Bioatla Inc
|
0.452 | 29.01M | 0 | -123.46M | -104.11M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.62 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.80 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.26 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.52 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.28 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Bioatla Inc Stock (BCAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-15-22 | Initiated | JMP Securities | Mkt Outperform |
| May-05-22 | Downgrade | Credit Suisse | Outperform → Neutral |
| Mar-21-22 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Jun-28-21 | Initiated | ROTH Capital | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | BTIG Research | Buy |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | JP Morgan | Overweight |
| Jan-11-21 | Initiated | Jefferies | Buy |
View All
Bioatla Inc Stock (BCAB) Latest News
Millennium Management LLC Reduces Stake in BioAtla Inc. - GuruFocus.com
Jane Street Group LLC Decreases Position in BioAtla, Inc. (NASDAQ:BCAB) - Defense World
BioAtla (NASDAQ:BCAB) Stock Price Down 6.1% – Here’s Why - Defense World
Bioatla stock hits 52-week low at $0.57 amid sharp decline - Investing.com
BioAtla (BCAB) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
**BioAtla Updates Corporate Presentation in 8-K Filing** - Defense World
BioAtla Announces Registered Direct Offering to Advance Clinical Programs to Key Inflection PointsSan Diego, Calif., December 20, 2024 – BioAtla, Inc. (NASDAQ: BCAB), a global clinical-stage biotechnology company, disclosed on December 19, 2024, that - Defense World
Bioatla stock hits 52-week low at $1.02 amid market challenges - Investing.com Australia
BioAtla Secures $9.2M for Clinical Program Advancements - TipRanks
BioAtla, Inc. Announces Registered Direct Offering to Advance Two Mid-Stage Clinical Programs to Key Inflection Points - The Manila Times
BioAtla Highlights Advancements in CAB Cancer Therapy - TipRanks
BioAtla announces $9.2 million stock and warrant sale - Investing.com
BioAtla announces $9.2 million stock and warrant sale By Investing.com - Investing.com Canada
BioAtla announces registered direct offering to advance two mid-stage clinical programs, shares fall - Seeking Alpha
BioAtla Secures $9.2M Funding Through Strategic Stock Offering to Advance Clinical Programs - StockTitan
Insiders Give Up US$66k As BioAtla Stock Drops To US$1.31 - Yahoo Finance
BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting - The Manila Times
BioAtla's Lung Cancer Drug Shows Promising 58% One-Year Survival Rate in Key Clinical Data - StockTitan
BioAtla's SWOT analysis: oncology biotech stock faces pivotal year By Investing.com - Investing.com South Africa
BioAtla's SWOT analysis: oncology biotech stock faces pivotal year - Investing.com
BioAtla Announces Upcoming Poster Presentation at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting - Quantisnow
BioAtla, Inc. (NASDAQ:BCAB) Q3 2024 Earnings Call Transcript - MSN
Michael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 trades - MSN
GSA Capital Partners LLP Purchases New Position in BioAtla, Inc. (NASDAQ:BCAB) - MarketBeat
BioAtla, Inc. (NASDAQ:BCAB) Sees Significant Drop in Short Interest - MarketBeat
HC Wainwright Weighs in on BioAtla FY2024 Earnings - Defense World
FY2024 Earnings Estimate for BioAtla Issued By HC Wainwright - MarketBeat
Analysis of TANG CAPITAL MANAGEMENT LLC's Recent Transaction in BioAtla Inc - GuruFocus.com
BioAtla (NASDAQ:BCAB) Rating Lowered to Neutral at HC Wainwright - Defense World
Michael Burry's Scion fund exits BioAtla, boosts Alibaba stake, adds puts: top Q3 trades (HPP:NYSE) - Seeking Alpha
HC Wainwright & Co. Downgrades BioAtla (BCAB) - MSN
BioAtla (NASDAQ:BCAB) Downgraded to "Neutral" Rating by HC Wainwright - MarketBeat
BioAtla Inc (BCAB) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Head to Head Review: Alector (NASDAQ:ALEC) vs. BioAtla (NASDAQ:BCAB) - Defense World
3 Promising US Penny Stocks With At Least $90M Market Cap - Simply Wall St
BioAtla Reports Q3 2024 Financial Results and Clinical Advances - TipRanks
BioAtla reports Q3 EPS (22c), consensus (36c) - TipRanks
BioAtla Reports Third Quarter 2024 Financial Results and Highlights Recent Progress - StockTitan
BioAtla (BCAB) Scheduled to Post Earnings on Thursday - MarketBeat
BioAtla to Announce Third Quarter 2024 Financial Results and Provide Business Highlights on November 7, 2024 - The Manila Times
Bioatla Inc Stock (BCAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):